ROCKVILLE, Md., Nov. 25, 2015 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused
on developing therapeutics to protect the gut microbiome while
targeting pathogen-specific diseases, announced today that
Rhonda Voskuhl, M.D., Professor,
Department of Neurology, Jack H. Skirball Chair in Multiple
Sclerosis Research and Director, Multiple Sclerosis Program at the
University of California, Los
Angeles (UCLA) David Geffen
School of Medicine, and the lead principal investigator of the
Phase 2 clinical trial that evaluated Trimesta™ as a
treatment for relapsing-remitting multiple sclerosis (RRMS) in
women, published additional clinical trial data in the journal,
Lancet Neurology.
As previously disclosed in July
2015, Synthetic Biologics was informed by UCLA that magnetic resonance imaging (MRI) analyses
were ongoing to evaluate changes in the brain that correlate with
improvements seen in clinical outcomes. With the publication of the
data by Dr. Voskuhl, the Company has received topline MRI data and
UCLA's related analysis. Upon receipt
of the MRI data set, as is typical with academic collaborations,
Synthetic Biologics commenced a thorough third party analysis in
order to confirm UCLA's results for
potential business development discussions. The Company continues
discussions with the neurology community and potential strategic
partners, as it determines next steps for Trimesta.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage
company developing therapeutics to protect the microbiome while
targeting pathogen-specific diseases. The Company's lead candidates
in Phase 2 development include: (1) SYN-004 which is designed to
protect the gut microbiome from the effects of certain commonly
used intravenous (IV) antibiotics for the prevention of C.
difficile infection and antibiotic-associated diarrhea (AAD),
and (2) SYN-010 which is intended to reduce the impact of methane
producing organisms in the gut microbiome to treat an underlying
cause of irritable bowel syndrome with constipation (IBS-C). In
addition, the Company is developing a Phase 2 oral estriol drug for
the treatment of relapsing-remitting multiple sclerosis (MS) and
cognitive dysfunction in MS, and in collaboration with Intrexon
Corporation (NYSE: XON), a preclinical stage monoclonal antibody
for the prevention and treatment of Pertussis and discovery stage
biotherapeutics for the treatment of phenylketonuria (PKU). For
more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases, forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding the continued
discussions with the neurology community and potential strategic
partners and the intended potential of SYN-010 and
SYN-004. The forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially from those set forth or implied by any forward-looking
statements. Important factors that could cause actual results to
differ materially from those reflected in Synthetic Biologics'
forward-looking statements include, among others, a failure to
receive the necessary regulatory approvals for commercialization of
Synthetic Biologics' therapeutics, a failure of Synthetic
Biologics' clinical trials, and those conducted by investigators,
to be commenced or completed on time or to achieve desired results,
a failure of Synthetic Biologics' clinical trials to receive
anticipated funding, a failure of Synthetic Biologics' products for
the prevention and treatment of diseases to be successfully
developed or commercialized, Synthetic Biologics' inability to
maintain its licensing agreements, or a failure by Synthetic
Biologics or its strategic partners to successfully commercialize
products and other factors described in Synthetic Biologics' report
on Form 10-K for the year ended December 31,
2014 and any other filings with the SEC. The information in
this release is provided only as of the date of this release, and
Synthetic Biologics undertakes no obligation to update any
forward-looking statements contained in this release on account of
new information, future events, or otherwise, except as required by
law.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-reports-that-data-from-the-phase-2-trimesta-clinical-trial-for-relapsing-remitting-multiple-sclerosis-were-published-by-lead-principal-investigator-300184560.html
SOURCE Synthetic Biologics, Inc.